Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Relacorilant i kombination med Nab-Paclitaxel i avanceret, platinresistent, højgradig epitelial ovarie-, primær peritoneal- eller æggelederkræft

24. september 2026 opdateret af: Corcept Therapeutics

Et fase 3-studie af relacorilant i kombination med Nab-Paclitaxel versus Nab-Paclitaxel monoterapi i avanceret, platinresistent, højgradig epitelial ovarie-, primær peritoneal- eller æggelederkræft (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Studieoversigt

Detaljeret beskrivelse

As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel.

Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

381

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1280AEB
        • Site 393
      • Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina, C1426ANZ
        • Site 381
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentina, X5004FHP
        • Site 415
      • Córdoba, Córdoba Province, Argentina, X5008 HHW
        • Site 401
      • Córdoba, Córdoba Province, Argentina, X5016
        • Site 395
    • Mendoza Province
      • Mendoza, Mendoza Province, Argentina, M5500AYB
        • Site 404
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Site 391
      • Rosario, Santa Fe Province, Argentina, S2000KDS
        • Site 412
    • New South Wales
      • St Leonards, New South Wales, Australien, 2065
        • Site 426
    • Queensland
      • Benowa, Queensland, Australien, 4217
        • Site 417
    • Victoria
      • Melbourne, Victoria, Australien, 3000
        • Site 414
      • Melbourne, Victoria, Australien, 3128
        • Site 419
      • Aalst, Belgien, 9300
        • Site 328
      • Brussels, Belgien, B- 1200
        • Site 109
      • Charleroi, Belgien, 6000
        • Site 326
      • Hasselt, Belgien, 3500
        • Site 325
      • Leuven, Belgien, 3000
        • Site 108
      • Liège, Belgien, B-4000
        • Site 327
      • Porto Alegre, Brasilien, 90035-001
        • Site 421
    • Brasília - DF
      • Brasília, Brasília - DF, Brasilien, 70297-400
        • Site 424
    • Ceará
      • Fortaleza, Ceará, Brasilien, 60170-170
        • Site 382
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 41950-640
        • Site 384
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasilien, 30210-040
        • Site 383
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasilien, 59062-000
        • Site 390
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brasilien, 22250-905
        • Site 380
    • São Paulo
      • São Paulo, São Paulo, Brasilien, 01321001
        • Site 376
      • São Paulo, São Paulo, Brasilien, 01327-001
        • Site 389
      • São Paulo, São Paulo, Brasilien, 01409-002
        • Site 413
      • São Paulo, São Paulo, Brasilien, 01509-900
        • Site 374
      • São Paulo, São Paulo, Brasilien, 01509010
        • Site 001
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Site 117
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Site 273
      • Cheltenham, Det Forenede Kongerige, GL53 7AN
        • Site 366
      • London, Det Forenede Kongerige, NW1 2PG
        • Site 055
      • Manchester, Det Forenede Kongerige, M20 4BX
        • Site 344
      • Northwood, Det Forenede Kongerige, HA6 2RN
        • Site 345
    • East Sussex
      • Brighton, East Sussex, Det Forenede Kongerige, BN2 1ES
        • Site 367
    • Somerset
      • Taunton, Somerset, Det Forenede Kongerige, TA1 5DA
        • Site 351
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85016
        • Site 318
      • Tucson, Arizona, Forenede Stater, 85719
        • Site 277
    • California
      • Irvine, California, Forenede Stater, 92618
        • Site 350
      • La Jolla, California, Forenede Stater, 92093
        • Site 364
      • Palo Alto, California, Forenede Stater, 94304
        • Site 150
      • San Francisco, California, Forenede Stater, 94109
        • Site 278
      • San Francisco, California, Forenede Stater, 94143
        • Site 014
      • Solvang, California, Forenede Stater, 93463
        • Site 316
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Site 032
    • Florida
      • Miami Beach, Florida, Forenede Stater, 33140
        • Site 335
      • Weston, Florida, Forenede Stater, 33331
        • Site 042
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Site 009
      • Atlanta, Georgia, Forenede Stater, 30342
        • Site 272
      • Gainesville, Georgia, Forenede Stater, 30548
        • Site 372
      • Savannah, Georgia, Forenede Stater, 31405
        • Site 291
    • Illinois
      • Evanston, Illinois, Forenede Stater, 60201
        • Site 315
      • Hinsdale, Illinois, Forenede Stater, 60521
        • Site 314
      • Urbana, Illinois, Forenede Stater, 61801
        • Site 346
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46260
        • Site 339
    • Kansas
      • Overland Park, Kansas, Forenede Stater, 66211
        • Site 200
      • Overland Park, Kansas, Forenede Stater, 66211
        • Site 334
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40241
        • Site 279
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Site 128
    • New Jersey
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Site 288
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87131
        • Site 292
    • New York
      • Flushing, New York, Forenede Stater, 11355
        • Site 275
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45242
        • Site 298
      • Cincinnati, Ohio, Forenede Stater, 45459
        • Site 304
    • Oregon
      • Portland, Oregon, Forenede Stater, 97210
        • Site 280
      • Portland, Oregon, Forenede Stater, 97213
        • Site 317
      • Portland, Oregon, Forenede Stater, 97239
        • Site 049
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forenede Stater, 18015
        • Site 337
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Site 127
    • South Dakota
      • Rapid City, South Dakota, Forenede Stater, 57701
        • Site 276
    • Tennessee
      • Germantown, Tennessee, Forenede Stater, 38138
        • Site 368
      • Nashville, Tennessee, Forenede Stater, 37203
        • Site 281
    • Texas
      • Austin, Texas, Forenede Stater, 78731
        • Site 229
      • Bedford, Texas, Forenede Stater, 76022
        • Site 312
      • Fort Worth, Texas, Forenede Stater, 76104
        • Site 297
      • San Antonio, Texas, Forenede Stater, 78240
        • Site 392
      • The Woodlands, Texas, Forenede Stater, 77380
        • Site 301
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23502
        • Site 300
      • Richmond, Virginia, Forenede Stater, 23298
        • Site 365
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Site 121
      • Lille, Frankrig, 59020
        • Site 306
      • Montpellier, Frankrig, 34298
        • Site 347
      • Nancy, Frankrig, 54100
        • Site 307
      • Nice, Frankrig, 06189
        • Site 310
      • Paris, Frankrig, 75015
        • Site 289
      • Plérin, Frankrig, 22190
        • Site 323
      • Haifa, Israel, 3436212
        • Site 309
      • Jerusalem, Israel, 911201
        • Site 080
      • Tel Aviv, Israel, 6423906
        • Site 203
      • Catania, Italien, 95126
        • Site 321
      • Legnago, Italien, 37045
        • Site 320
      • Milan, Italien, 20141
        • Site 122
      • Pavia, Italien, 27100
        • Site 295
      • Roma, Italien, 161
        • Site 161
      • Rome, Italien, 00168
        • Site 124
      • Torino, Italien, 10128
        • Site 293
      • Treviso, Italien, 31100
        • Site 319
      • Gdynia, Polen, 81-519
        • Site 341
      • Poznan, Polen, 61-886
        • Site 331
      • Siedlce, Polen, 08-110
        • Site 329
      • Badalona, Spanien, 08916
        • Site 349
      • San Sebastián, Spanien, 20014
        • Site 311
      • Valencia, Spanien, 46026
        • Site 330
      • Gyeonggi-do, Sydkorea, 10408
        • Site 397
      • Seoul, Sydkorea, 03080
        • Site 399
      • Seoul, Sydkorea, 03722
        • Site 398
      • Seoul, Sydkorea, 05505
        • Site 403
      • Seoul, Sydkorea, 06273
        • Site 400
      • Seoul, Sydkorea, 06351
        • Site 396
      • Seoul, Sydkorea, 08308
        • Site 402
      • Seoul, Sydkorea, 42601
        • Site 409
      • Budapest, Ungarn, 1122
        • Site 322
      • Debrecen, Ungarn, 4032
        • Site 290
      • Győr, Ungarn, 9024
        • Site 348

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures.
  • Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
  • Patients must have platinum-resistant disease (defined as RECIST v1.1 defined progression <6 months from completion of a platinum-containing therapy).
  • Must consent to provide archival tumor-tissue block or slides. Patients may consent to an optional tumor biopsy if archival tumor is unavailable.
  • Has a life expectancy of ≥3 months.
  • At least one lesion that meets the definition of measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Able to comply with protocol requirements.
  • Able to swallow and retain oral medication and does not have uncontrolled emesis.
  • Received at least 1 but ≤3 lines of prior systemic anticancer therapy and at least 1 prior line of platinum therapy and prior treatment with bevacizumab is required.
  • Has adequate organ function meeting the following laboratory-test criteria: Absolute neutrophil count (ANC) ≥1500 cells/mm^3, Platelet count ≥100,000/mm^3, Hemoglobin ≥9 g/dL, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases, Total bilirubin ≤1.5 × ULN, and Albumin ≥3 g/dL, and creatinine clearance >40 mL/min/1.73 m^2 (measured or estimated).
  • Negative pregnancy test for patients of childbearing potential; patients of childbearing potential must agree to use highly effective contraceptive method(s); hormonal contraceptives are not allowed.
  • Coronavirus disease (COVID-19) approved vaccines are accepted concomitant medications when recommended by the Investigator.

Exclusion Criteria:

  • Has clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to ≤Grade 1 prior to randomization.
  • Has had any major surgery within 4 weeks prior to randomization.
  • Has low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.
  • Has primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤1 month of the last dose of first-line platinum-containing chemotherapy.
  • Has not received prior bevacizumab treatment.
  • Has been treated with the following prior to randomization: chemotherapy, immunotherapy, investigational agent treatments for disease under study within 28 days before first dose of study drug, radiotherapy not completed at least 2 weeks prior to first dose of study drug, hormonal anticancer therapies within 7 days of first dose of study drug, and systemic, inhaled, or prescription strength topical corticosteroids within 21 days of first dose of study drug.
  • Has received wide-field radiation to more than 25% of marrow-bearing areas.
  • Has toxicities of prior therapies that have not resolved by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, ≤Grade 1.
  • Requires treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses.
  • Has a history of severe hypersensitivity or severe reaction to any of the study drugs.
  • Is receiving concurrent treatment with mifepristone or other glucocorticoid receptor (GR) modulators.
  • Has peripheral neuropathy from any cause >Grade 1.
  • Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 1 month after the last dose of relacorilant, or 6 months after the last dose of nab-paclitaxel whichever is the longest.
  • Has clinically significant uncontrolled condition(s) or condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation.
  • Has current chronic/active infection with human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus.
  • Has any untreated or symptomatic central nervous system (CNS) metastases.
  • Patients with a history of other malignancy within 3 years prior to randomization.
  • Is taking a concomitant medication that is a strong cytochrome P450 (CYP)3A inhibitor or strong CYP3A inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
  • Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
  • Has received a live vaccine within 30 days prior to the study start date.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2

Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.

Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.

Andre navne:
  • Lifyorli

Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Aktiv komparator: Nab-paclitaxel 100 mg/m^2

Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.

Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Tidsramme: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions.

Up to 20 months
Overall Survival
Tidsramme: Up to 32 months

Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates.

Up to 32 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PFS as Assessed by the Investigator
Tidsramme: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) by RECIST v1.1, or death due to any cause, whichever occurs first.

Up to 20 months
Objective Response as Assessed by the Investigator
Tidsramme: Up to 20 months

Objective response was assessed as the proportion of patients with measurable disease at baseline who attained complete response (CR) or partial response (PR). Confirmation of the response was not required for this outcome measure per RECIST v1.1 criteria for randomized controlled clinical trials. Responses were assessed by imaging, using RECIST v1.1 criteria for target lesions: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Up to 20 months
Best Overall Response as Assessed by the Investigator
Tidsramme: Up to 20 months

Best overall response was assessed as the proportion of patients with at least 1 post Baseline scan who attained CR, PR, stable disease (SD), or PD as best response by RECIST v1.1.

Up to 20 months
Duration of Confirmed Responses as Assessed by the Investigator
Tidsramme: From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)

The median duration of response is presented for confirmed responses (CR or PR) per RECIST v1.1. Duration of response was from the first documented and confirmed response to the first objectively documented PD as assessed by the Investigator, or death due to any cause, whichever occurs first.

From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
Clinical Benefit Rate at 24 Weeks as Assessed by BICR and the Investigator
Tidsramme: 24 weeks

Clinical benefit rate was assessed as the proportion of patients who attained CR, PR, or stable disease (SD) for 24 weeks per RECIST v1.1 as assessed by BICR and as assessed by the Investigator.

24 weeks
Cancer Antigen (CA)-125 Response
Tidsramme: Up to 24 months

CA-125 response was assessed per Gynecologic Cancer Intergroup (GCIG) criteria defined as ≥50% reduction in CA-125 from a pretreatment sample and maintained for ≥28 days in patients with a pretreatment sample that is at least twice the upper limit of the reference range within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level fell to within the reference range were classified as CA-125 complete responders.

Up to 24 months
Combined Overall Response Rate by RECIST v1.1 and CA-125 Defined by GCIG Criteria
Tidsramme: Up to 15 months

Combined response was assessed as the proportion of patients with tumor response per RECIST v1.1 assessed by the investigator and for CA-125 response per GCIG criteria.

Up to 15 months
Number of Patients With One or More Adverse Events
Tidsramme: Up to 22 months
Up to 22 months
Number of Patients Who Discontinued the Study Treatment Due to an Adverse Event
Tidsramme: Up to 25 months
Up to 25 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studieleder: Adrian Jubb, MBChB, PhD, FRCPath, Corcept Therapeutics

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. juni 2022

Primær færdiggørelse (Faktiske)

31. marts 2025

Studieafslutning (Anslået)

1. december 2026

Datoer for studieregistrering

Først indsendt

4. februar 2022

Først indsendt, der opfyldte QC-kriterier

16. februar 2022

Først opslået (Faktiske)

25. februar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CORT125134-556
  • GOG-3073 (Anden identifikator: Gynecologic Oncology Group)
  • ROSELLA Study 556 (Anden identifikator: Corcept Therapeutics)
  • ENGOT-OV72 (Anden identifikator: European Network of Gynaecological Oncological Trial Groups)
  • APGOT-Ov10 (Anden identifikator: Asia-Pacific Gynecologic Oncology Trials Group)
  • LACOG 0223 (Anden identifikator: Latin American Cooperative Oncology Group)
  • ANZGOG2221/2023 (Anden identifikator: Australia New Zealand Gynaecological Oncology Group)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner